MarketCap
Facebook
X
Telegram
Aeglea BioTherapeutics Financial Ratios 2025-2011 | AGLE
Brief overview of Aeglea BioTherapeutics's multiples and efficiency
The review covers five available annual periods spanning 2018 to 2023.
Key multiples at the end of the period are P/S 488.77x (median 48.2x), P/B 1.4x (median 1.4x). The combined multiple level is about 457% above the company's historical norm, leaving less valuation cushion.
Returns on assets and capital are represented by ROE -21.7%, ROA -20%, ROCE -29.3%. Returns below zero mean resources are not producing positive profit. Recovery in operating results is the main reference point.
Price, earnings and growth produce a PEG of 1.6x, a neutral level if forecasts are realistic.
Conclusion
Aeglea BioTherapeutics's valuation is above historical references while efficiency remains restrained, increasing sensitivity to weak reports.
Annual Financial Ratios Aeglea BioTherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
- | -3.5 | -1.3 | -0.0 | -0.2 | -5.2 | -2.9 | -4.2 | -3.8 | -1.8 | - | - | - | - | - |
P/S |
- | - | 488.8 | 0.6 | 0.7 | 19229.8 | - | 48.2 | 20.0 | 8.5 | - | - | - | - | - |
EPS |
- | - | - | -24.9 | -25.0 | -1.5 | -2.5 | -2.1 | -1.8 | -2.2 | -19.2 | - | - | - | - |
EV (Enterprise Value) |
-23.2 M | 725 M | 317 M | -12.7 M | 21.5 M | 352 M | 230 M | 175 M | 96.9 M | -4.39 M | -26.7 M | -1.56 M | 1.41 M | - | - |
EBITDA per Share |
- | - | -6.7 | -24.7 | -24.4 | -1.51 | -2.5 | -2.17 | -1.81 | -2.22 | - | - | - | - | - |
EV/EBITDA |
-4.3 | -4.4 | -2.6 | -3.7 | -3.3 | 0.4 | - | - | - | - | - | ||||
PEG |
-0.01 | -0.0 | -0.0 | -0.0 | 1.6 | 0.19 | 0.23 | -0.2 | 0.06 | - | - | - | - | - | |
P/B |
- | 1.4 | 1.6 | 0.0 | 0.1 | 3.0 | 3.8 | 2.8 | 2.1 | 0.6 | - | - | - | - | - |
P/CF |
- | -4.6 | -4.3 | -0.0 | -0.2 | -5.5 | -3.4 | -5.7 | -4.1 | -2.1 | - | - | - | - | - |
ROE % |
-21.70 | -40.17 | -184.11 | -166.61 | -78.39 | -57.85 | -130.25 | -65.77 | -54.11 | -34.46 | - | - | - | - | - |
ROA % |
-19.95 | -34.19 | -99.10 | -117.81 | -59.86 | -50.05 | -94.07 | -57.05 | -48.57 | -32.35 | - | - | - | - | - |
ROCE % |
-29.30 | -40.28 | -131.67 | -168.53 | -78.21 | -58.27 | -123.93 | -67.35 | -54.86 | -34.72 | - | - | - | - | - |
Current Ratio |
12.4 | 6.7 | 4.7 | 3.4 | 4.2 | 7.4 | 4.1 | 7.5 | 9.8 | 16.8 | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | 215.8 | 95.8 | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Aeglea BioTherapeutics
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | - | - | - | - | - | -1.36 | -0.86 | -1.2 | - | -9.34 | -56.79 | -4.89 | - | -4.84 | -0.27 | -0.37 | - | -0.31 | -0.1 | -0.28 | -0.35 | -0.29 | -0.4 | -0.57 | -0.65 | -0.66 | -0.55 | -0.59 | -0.62 | -0.54 | -0.46 | -0.49 | -0.39 | -0.48 | -0.47 | -0.47 | -0.41 | -0.47 | -0.46 | -7.1 | -6.36 | -5.57 | -2.44 | -4.71 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | - | - | - | - | - | - | - | - | - | - | - | -4.89 | - | -4.66 | -0.27 | -0.36 | - | -0.29 | -0.1 | -0.27 | -0.47 | -0.28 | -0.4 | -0.57 | -0.75 | -0.66 | -0.56 | -0.61 | -0.63 | -0.55 | -0.46 | -0.49 | -0.4 | -0.48 | -0.47 | -0.47 | -0.41 | -0.47 | -0.46 | -7.08 | -5.28 | -5.48 | -2.38 | -4.28 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-23.26 | -19.79 | -40.87 | -59.50 | -61.82 | -60.26 | -43.92 | -6.49 | 108.57 | 66.28 | 39.29 | -4.04 | -135.25 | -93.15 | -113.04 | -105.94 | -85.16 | -40.35 | -56.60 | -49.60 | -59.18 | -57.85 | -77.38 | -100.39 | -115.07 | -130.25 | -116.57 | -98.33 | -82.30 | -65.77 | -56.56 | -54.52 | -53.74 | -54.11 | -49.94 | -44.20 | -39.65 | -34.46 | -7.80 | 17.48 | 32.53 | 50.86 | 32.91 | 17.54 | 11.11 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-20.28 | -16.89 | -33.28 | -47.46 | -49.55 | -34.29 | -53.64 | -56.60 | -136.84 | -143.61 | -163.52 | -164.09 | -104.33 | -78.68 | -94.41 | -60.85 | -65.50 | -31.52 | -45.57 | -40.99 | -49.60 | -50.05 | -61.84 | -76.62 | -85.02 | -94.07 | -87.40 | -76.79 | -67.24 | -57.05 | -49.44 | -48.16 | -47.87 | -48.57 | -45.18 | -40.44 | -36.71 | -32.35 | -34.49 | -34.02 | -29.62 | -29.22 | -18.91 | -10.08 | -6.38 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-41.00 | -32.80 | -49.72 | -54.14 | -56.73 | -60.09 | -52.61 | -28.22 | 60.36 | 28.38 | 0.62 | -34.62 | -138.05 | -94.05 | -113.93 | -106.04 | -85.03 | -40.23 | -56.51 | -49.60 | -59.38 | -58.27 | -78.45 | -102.35 | -117.92 | -133.71 | -119.94 | -101.24 | -84.59 | -67.42 | -57.89 | -55.62 | -54.63 | -54.98 | -50.62 | -44.74 | -40.11 | -34.79 | -7.99 | 17.41 | 32.58 | 50.95 | 32.95 | 17.57 | 11.12 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
8.2 | 12.4 | 10.2 | 6.5 | 6.5 | 6.7 | 4.5 | 7.1 | 6.0 | 4.7 | 3.2 | 1.0 | 2.8 | 3.4 | 3.8 | - | 3.9 | 4.2 | 4.8 | 5.3 | 4.1 | 7.4 | 7.4 | 7.4 | 7.4 | 3.6 | 3.6 | 3.6 | 3.6 | 7.5 | 7.5 | 7.5 | 7.5 | 9.8 | 9.8 | 9.8 | 9.8 | 16.4 | 16.4 | 16.4 | 16.4 | 15.2 | 15.2 | 15.2 | 15.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 71.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 71.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 71.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Aeglea BioTherapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Irlanda
